Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 31.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,039 shares of the company’s stock after selling 9,705 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Denali Therapeutics were worth $429,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of DNLI. Norges Bank purchased a new stake in Denali Therapeutics during the fourth quarter worth approximately $21,717,000. Vanguard Group Inc. boosted its position in Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock worth $244,993,000 after purchasing an additional 843,996 shares during the period. Balyasny Asset Management L.P. increased its holdings in Denali Therapeutics by 822.4% in the 4th quarter. Balyasny Asset Management L.P. now owns 416,074 shares of the company’s stock valued at $8,480,000 after purchasing an additional 370,966 shares in the last quarter. Millennium Management LLC raised its position in Denali Therapeutics by 571.8% in the fourth quarter. Millennium Management LLC now owns 404,224 shares of the company’s stock valued at $8,238,000 after purchasing an additional 344,056 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Denali Therapeutics by 19.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,855,036 shares of the company’s stock valued at $37,805,000 after purchasing an additional 295,594 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on DNLI. Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Robert W. Baird decreased their price target on Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating for the company in a report on Thursday, May 8th. Wedbush dropped their price objective on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 7th. B. Riley restated a “buy” rating and issued a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $33.79.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $14.26 on Wednesday. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -5.17 and a beta of 1.49. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company’s 50-day simple moving average is $14.20 and its 200-day simple moving average is $19.87.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.07). During the same period in the prior year, the company earned ($0.68) earnings per share. As a group, research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.